Asian, Black, and Other race breast cancer patients with type 2 diabetes were less likely than White patients to receive GLP-1RAs.
Evidence
Retrospective TriNetX electronic health record cohort of 119,430 breast cancer patients with type 2 diabetes from 2005-2024, using propensity-matched race comparisons.
Caveat
The EHR cohort identifies treatment-use disparities but cannot determine the clinical, insurance, preference, or system-level causes.
Simplified
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer significant benefits for patients with type 2 diabetes mellitus (T2DM), including improved glycemic control, weight reduction, cardiovascular protection, and reduced all-cause mortality, which are particularly relevant to breast cancer survivorship. Disparities in access may worsen inequities in care. Using the TriNetX national electronic health record database, we conducted a retrospective cohort study of 119,430 breast cancer patients with type 2 diabetes (2005-2024; mean age 66.1 ± 11.4 years; 67.2% White, 22.9% Black, 5.7% Asian, 4.2% Other). After propensity matching, compared with White patients, Asian ( 0.64, 95% CI 0.58-0.71), Black (HR 0.78, 95% CI 0.75-0.81), and Other race patients (HR 0.90, 95% CI 0.83-0.97) were significantly less likely to receive GLP-1RAs. These disparities persisted among overweight and obese subgroups: Asian (HR 0.78, 95% CI 0.68-0.88), Black (HR 0.78, 95% CI 0.74-0.81), and Other patients (HR 0.83, 95% CI 0.72-0.95). These findings underscore the urgent need to address inequitable access to GLP-1RAs in breast cancer survivorship care.
Key numbers
18,026 patients
Prescription Rate
15.1% of the overall study population were prescribed GLP-1RAs.
0.64
Lower Likelihood of Prescription
for Asian patients compared to White patients.
0.78
Lower Likelihood of Prescription
for Black patients compared to White patients.
Full Text
We can’t show the full text here under this license.
GLP-1 Therapies